ALX-0061

BIOLOGICAL6 trials

Sponsors

Ablynx, a Sanofi company

Conditions

Lupus Erythematosus, SystemicRheumatoid Arthritis

Phase 1

Study to Assess Safety and Efficacy of Anti-Interleukin 6-receptor (IL6R) Nanobody in Rheumatoid Arthritis (RA) Patients

CompletedNCT01284569

Ablynx, a Sanofi companyRheumatoid Arthritis

Start: 2011-03-31End: 2012-09-30Updated: 2019-01-04

ALX-0061 Phase I Bioavailability Study in Healthy Volunteers

CompletedNCT02101073

Ablynx, a Sanofi companyRheumatoid Arthritis

Start: 2014-03-31End: 2014-07-31Updated: 2019-01-04

Phase 2

A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid Arthritis

CompletedNCT02287922

Ablynx, a Sanofi companyRheumatoid Arthritis

Start: 2015-03-31End: 2016-07-31Updated: 2019-08-21

A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis

CompletedNCT02309359

Ablynx, a Sanofi companyRheumatoid Arthritis

Start: 2015-01-31End: 2016-08-31Updated: 2019-08-21

A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus

CompletedNCT02437890

Ablynx, a Sanofi companyLupus Erythematosus, Systemic

Start: 2015-07-31End: 2018-01-31Updated: 2019-02-26

An Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of ALX-0061 in Subjects With Rheumatoid Arthritis

CompletedNCT02518620

Ablynx, a Sanofi companyRheumatoid Arthritis

Start: 2015-07-31End: 2018-08-31Updated: 2019-07-30